Alkaptonuria is a novel human secondary amyloidogenic disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 11, 2012, Pages 1682-1691

  Millucci, Lia ^a   Spreafico, Adriano ^a   Tinti, Laura ^a   Braconi, Daniela ^a   Ghezzi, Lorenzo ^a   Paccagnini, Eugenio ^a   Bernardini, Giulia ^a   Amato, Loredana ^a   Laschi, Marcella ^a   Selvi, Enrico ^a   Galeazzi, Mauro ^a   Mannoni, Alessandro ^a,b   Benucci, Maurizio ^b   Lupetti, Pietro ^a   Chellini, Federico ^a   Orlandini, Maurizio ^a   Santucci, Annalisa ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Amyloidosis; Homogentisic acid; Ochronosis

Indexed keywords

AMYLOID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; COLLAGEN FIBER; IMMUNOGLOBULIN LIGHT CHAIN; MELANIN; METHOTREXATE; SERUM AMYLOID A; SERUM AMYLOID P;

ABDOMINAL FAT; ADULT; ALKAPTONURIA; AMYLOIDOSIS; ARTICLE; BONE TISSUE; CARTILAGE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; SALIVARY GLAND; SALIVARY GLAND BIOPSY; SYNOVIUM;

AGED; ALKAPTONURIA; AMYLOIDOSIS; CARTILAGE; CHONDROCYTES; FEMALE; HOMOGENTISATE 1,2-DIOXYGENASE; HOMOGENTISIC ACID; HUMANS; MALE; MELANINS; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; SERUM AMYLOID A PROTEIN; SERUM AMYLOID P-COMPONENT; SYNOVIAL FLUID;

EID: 84865087617     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.07.011     Document Type: Article

References (51)

1. Selvi E., Manganelli S., Mannoni A., Benucci M., Minacci C., Marcolongo R. Chronic ochronotic arthritis: clinical, arthroscopic, and pathologic findings. J. Rheumatol. 2000, 27:2272-2274.
2. Martin J.P., Batkoff B. Homogentisic acid autoxidation and oxygen radical generation: implications for the etiology of alkaptonuric arthritis. Free Radic. Biol. Med. 1987, 3:241-250.
3. Helliwell T.R., Gallagher J.A., Ranganath L. Alkaptonuria-a review of surgical and autopsy pathology. Histopathology 2008, 53:503-512.
4. Mathews J., Padhan P., John S., David S. Acute anterior uveitis as the initial presentation of alkaptonuria. J. Postgrad. Med. 2009, 55(1):35-37.
5. Pettit S.J., Fisher M., Gallagher J.A., Ranganath L.R. Cardiovascular manifestations of alkaptonuria. J. Inherit. Metab. Dis. 2011, 34:1177-1181.
6. Butany J.W., Naseemuddin A., Moshkowitz Y., Nair V. Ochronosis and aortic valve stenosis. J. Card. Surg. 2006, 21:182-184.
7. D. Braconi, G. Bernardini, C. Bianchini, M. Laschi, L. Millucci, L. Amato, L. Tinti, T. Serchi, F. Chellini, A. Spreafico, A. Santucci, Biochemical and proteomic characterization of alkaptonuric chondrocytes, J. Cell. Physiol. (2011) 227(9) (2012) 3333-3343.
8. Braconi D., Laschi M., Amato L., Bernardini G., Millucci L., Marcolongo R., Cavallo G., Spreafico A., Santucci A. Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis. Rheumatology (Oxford) 2010, 49:1975-1983.
9. Braconi D., Laschi M., Taylor A.M., Bernardini G., Spreafico A., Tinti L., Gallagher J.A., Santucci A. Proteomic and redox-proteomic evaluation of homogentisic acid and ascorbic acid effects on human articular chondrocytes. J. Cell. Biochem. 2010, 111:922-932.
10. Tinti L., Spreafico A., Braconi D., Millucci L., Bernardini G., Chellini F., Cavallo G., Selvi E., Galeazzi M., Marcolongo R., Gallagher J.A., Santucci A. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model. J. Cell. Physiol. 2010, 225:84-91.
11. Tinti L., Taylor A.M., Santucci A., Wlodarski B., Wilson P.J., Jarvis J.C., Fraser W.D., Davidson J.S., Ranganath L.R., Gallagher J.A. Development of an in vitro model to investigate joint ochronosis in alkaptonuria. Rheumatology (Oxford) 2011, 50:271-277.
12. Tinti L., Spreafico A., Chellini F., Galeazzi M., Santucci A. A novel ex vivo organotypic culture model of alkaptonuria-ochronosis. Clin. Exp. Rheumatol. 2011, 29:693-696.
13. Taylor A.M., Wlodarski B., Prior I.A., Wilson P.J., Jarvis J.C., Ranganath L.R., Gallagher J.A. Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology (Oxford) 2010, 49:1412-1414.
14. Momohara S., Okamoto H., Yamanaka H. Chondrocyte of rheumatoid arthritis serve as a source of intra-articular acute-phase serum amyloid A protein. Clin. Chim. Acta 2008, 398:155-156.
15. Romhányi G. Selective differentiation between amyloid and connective tissue structures based on the collagen specific topo-optical staining reaction with Congo Red. Virchows Arch. 1971, 354:209-222.
16. Bély M., Apáthy A. Histochemical and immunohistochemical differential diagnosis of amyloidosis-a brief illustrated essay and personal experience with Romhányi's method. Amyloid: Int. J. Exp. Clin. Invest. 2000, 7:212-217.
17. Saeed S.M., Fine G. Thioflavin T for amyloid detection. Am. J. Clin. Pathol. 1967, 47:588-593.
18. M.M. Picken, G.A. Herrera, Th-T stain: an easier and more sensitive method for amyloid detection, in: M.M. Picken, A. Dogan, G.A. Herrera, Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations, Current Clinical Pathology, Series Editor: A. Giordano, Springer - Humana Press, 2012, pp. 187-190.
19. Bernardini G., Braconi D., Spreafico A., Santucci A. Post-genomics of bone metabolic dysfunctions and neoplasias. Proteomics 2012, 12:708-721.
20. Hachulla E., Janin A., Flipo R.M., Saile R., Facon T., Bataille D., Vanhille P., Hatron P.Y., Devulder B., Duquesnoy B. Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients. Arthritis Rheum. 1993, 36:691-697.
21. van Gameren I.I., Hazenberg B.P., Bijzet J., Haagsma E.B., Vellenga E., Posthumus M.D., Jager P.L., van Rijswijk M.H. Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. Arthritis Care Res. (Hoboken) 2010, 62:296-301.
22. Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod. Rheumatol. 2008, 18:109-118.
23. van der Hilst J.C., Kluve-Beckerman B., van der Meer J.W., Simon A. Cathepsin D activity protects against development of type AA amyloid fibrils. Eur. J. Clin. Invest. 2009, 39:412-416.
24. Evans C.G., Wisen S., Gestwicki J.E. Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J. Biol. Chem. 2006, 281:33182-33191.
25. Meehan S., Knowles T.P., Baldwin A.J., Smith J.F., Squires A.M., Clements P., Treweek T.M., Ecroyd H., Tartaglia G.G., Vendruscolo M., Macphee C.E., Dobson C.M., Carver J.A. Characterisation of amyloid fibril formation by small heat-shock chaperone proteins human alphaA-, alphaB- and R120G alphaB-crystallins. J. Mol. Biol. 2007, 372:470-484.
26. Lachmann H.J., Goodman H.J., Gilbertson J.A., Gallimore J.R., Sabin C.A., Gillmore J.D., Hawkins P.N. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 2007, 356:2361-2371.
27. Castillo E.C.G., Kourí J.B. A new role for chondrocytes as non-professional phagocytes. An in vitro study. Microsc. Res. Tech. 2004, 64:269-278.
28. Ward M.W., Concannon C.G., Whyte J., Walsh C.M., Corley B., Prehn J.H. The amyloid precursor protein intracellular domain(AICD) disrupts actin dynamics and mitochondrial bioenergetics. J. Neurochem. 2010, 113:275-284.
29. Ji L., Chauhan V., Mehta P., Wegiel J., Mehta S., Chauhan A. Relationship between proteolytically cleaved gelsolin and levels of amyloid-β protein in the brains of Down syndrome subjects. J. Alzheimers Dis. 2010, 22:609-617.
30. Güntert A., Campbell J., Saleem M., O'Brien D.P., Thompson A.J., Byers H.L., Ward M.A., Lovestone S. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J. Alzheimers Dis. 2010, 21:585-596.
31. Nag S., Ma Q., Wang H., Chumnarnsilpa S., Lee W.L., Larsson M., Kannan B., Hernandez-Valladares M., Burtnick L.D., Robinson R.C. Ca2+ binding by domain 2 plays a critical role in the activation and stabilization of gelsolin. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13713-13718.
32. Kim S.H., Creemers J.W., Chu S., Thinakaran G., Sisodia S.S. Proteolytic processing of familial British dementia-associated BRI variants: evidence for enhanced intracellular accumulation of amyloidogenic peptides. J. Biol. Chem. 2002, 277:1872-1877.
33. Watt B., van Niel G., Fowler D.M., Hurbain I., Kelvin K.L., Stayrook S.E., Lemmon M.A., Raposo G., Shorter J., Kelly J.W., Marks M.S. N-terminal domains elicit formation of functional Pmel17 amyloid fibrils. J. Biol. Chem. 2009, 284:35543-35555.
34. Kelly J.W., Balch W.E. Amyloid as a natural product. J. Cell Biol. 2003, 161:461-462.
35. Gaines J.J. The pathology of alkaptonuric ochronosis. Hum. Pathol. 1989, 20:40-46.
36. Laschi M., Tinti L., Braconi D., Millucci L., Ghezzi L., Amato L., Selvi E., Spreafico A., Bernardini G., Santucci A. Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: implications in alkaptonuria. J. Cell. Physiol. 2012, 227:3254-3257.
37. Heng A.E., Courbebaisse M., Kemeny J.L., Matesan R., Bonniol C., Deteix P., Souweine B. Hemolysis in a patient with alkaptonuria and chronic kidney failure. Am. J. Kidney Dis. 2010, 56:e1-e4.
38. Bulow C., Rosenberg J. Intrahepatic gallstones in patient with alkaptonuria. Ugeskr. Laeger 2009, 171:2198-2199.
39. Raina S., Mahesh D.M., Kaushal S.S., Gupta D., Dhiman D.S., Negi A., Sharma S. Alkaptonuria and intramedullary calcification. J. Assoc. Physicians India 2008, 56:552-555.
40. Kolar J., Krizek V. Radiographic symptoms of alkaptomuric ochronosis. Fortschr. Geb. Rontgenstr. Nuklearmed. 1968, 109:203-208.
41. Parambil J.G., Daniels C.E., Zehr K.J., Utz J.P. Alkaptonuria diagnosed by flexible bronchoscopy. Chest 2005, 128:3678-3680.
42. Obici L., Raimondi S., Lavatelli F., Bellotti V., Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum. 2009, 61:1435-1440.
43. Gillmore J.D., Lovat L.B., Persey M.R., Pepys M.B., Hawkins P.N. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001, 358:24-29.
44. Cox T.F., Ranganath L. A quantitative assessment of alkaptonuria: testing the reliability of two disease severity scoring systems. J. Inherit. Metab. Dis. 2011, 34:1153-1162.
45. Ranganath L.R., Cox T.F. Natural history of alkaptonuria revisited: analyses based on scoring systems. J. Inherit. Metab. Dis. 2011, 34:1141-1151.
46. Bewely M.A., Pham T.K., Marriott H.M., Noirel J., Chu H.-P., Ow S.Y., Ryazanov A.G., Read R.C., Whyte M.K.B., Chain B., Wright P.C., Dockrell D.H. Proteomic evaluation and validation of cathepsin D regulated proteins in macrophages exposed to Streptococcus pneumoniae. Mol. Cell. Proteomics 2011, 10.1074:1-14.
47. van der Hilst J.C. Recent insights into the pathogenesis of type AA amyloidosis. ScientificWorldJournal 2011, 11:641-650.
48. Fowler D.M., Koulov A.V., Alory-Jost C., Marks M.S., Balch W.E., Kelly J.W. Functional amyloid formation within mammalian tissue. PLoS Biol. 2006, 4:e6.
49. Rao K.S., Hegde M.L., Anitha S., Musicco M., Zucca F.A., Turro N.J., Zecca L. Amyloid beta and neuromelanin-toxic or protective molecules? The cellular context makes the difference. Prog. Neurobiol. 2006, 78:364-373.
50. Aquaron R., Fayet G., Barthet C., Desire S., Viallet F. Parkinson disease and alkaptonuria: fortuitous association or striatonigral ochronosis?. Rev. Neurol. (Paris) 1995, 151:63-66.
51. Introne W.J., Perry M.B., Troendle J., Tsilou E., Kayser M.A., Suwannarat P., O'Brien K.E., Bryant J., Sachdev V., Reynolds J.C., Moylan E., Bernardini I., Gahl W.A. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol. Genet. Metab. 2011, 103:307-314.